{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-231646","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.640736+00:00","generated_at":"2026-06-10T22:12:47.593877+00:00","sec_items":["3.03","5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aeglea Biotherapeutics effects 1-for-25 reverse stock split and reduces authorized shares to 20M","bullets":["Reverse stock split at 1-for-25 ratio effective Sept 8, 2023; no fractional shares issued; cash in lieu.","Authorized common shares reduced from 500M to 20M.","Proportional adjustments to Series A preferred conversion, outstanding warrants, and equity awards.","Corporate presentation: adjusted total capitalization ~47.7M shares as-converted as of June 22, 2023.","2022 net loss per share restated to $(24.86) on weighted-average shares of 3.37M post-split."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-231646","json":"https://secwatch.observer/filing/0001193125-23-231646.json","markdown":"https://secwatch.observer/filing/0001193125-23-231646.md","text":"https://secwatch.observer/filing/0001193125-23-231646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523231646/0001193125-23-231646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523231646/d548916d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:12:47.593877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4176ac433fb188976548a8e4e82ece8006c5ca21","claim":"Spyre Therapeutics, Inc.: Filed Certificate of Amendment to Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split and reduction of authorized shares from 500,000,000 to 20,000,000 (effective 2023-09-08).","evidence_excerpt":"To effect the Reverse Stock Split and the Authorized Shares Reduction, on September 7, 2023, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Amendment”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523231646/0001193125-23-231646-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-09-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}